ARS Pharmaceuticals, Inc. (SPRY) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2024
Loading P/E history...
SPRY Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, ARS Pharmaceuticals, Inc. (SPRY) trades at a price-to-earnings ratio of -5.0x, with a stock price of $8.74 and trailing twelve-month earnings per share of $-1.74.
The current P/E is 103% below its 5-year average of 150.7x. Over the past five years, SPRY's P/E has ranged from a low of 150.7x to a high of 150.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, SPRY trades at a 123% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, SPRY trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SPRY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SPRY P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 13.6Lowest | - | -26% | |
| $8B | 25.0 | 1.09 | -25% | |
| $356B | 85.0 | - | -1% | |
| $5B | 46.9 | - | -72% | |
| $90B | 28.6 | 0.73Best | +15% | |
| $43B | 28.5 | - | +87%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SPRY Historical P/E Data (2024–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $10.55 | $0.07 | 150.7x | +0% |
Average P/E for displayed period: 150.7x
See SPRY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SPRY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SPRY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSPRY — Frequently Asked Questions
Quick answers to the most common questions about buying SPRY stock.
Is SPRY stock overvalued or undervalued?
SPRY trades at -5.0x P/E, below its 5-year average of 150.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SPRY's valuation compare to peers?
ARS Pharmaceuticals, Inc. P/E of -5.0x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is SPRY's PEG ratio?
SPRY PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2024.